The therapeutic effects of PJ34. [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)- N,N-dimethylacetamide, HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 1053-1061

  Scott, Gwen S ^a,c   Kean, Rhonda B ^a   Mikheeva, Tatiana ^a   Fabis, Marzena J ^a   Mabley, Jon G ^b   Szabó, Csaba ^b   Hooper, D Craig ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b INOTEK CORPORATION   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MYELIN; MYELIN BASIC PROTEIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; EXPERIMENTAL ANIMAL; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; INFLAMMATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERCELLULAR ADHESION MOLECULE-1; MICE; MYELIN BASIC PROTEINS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; SPINAL CORD DISEASES; T-LYMPHOCYTES; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4243068535     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.063214     Document Type: Article

References (40)

1. Bettelli E and Nicholson LB (2000) The role of cytokines in experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp 48:389-398.
2. Broomhead C and Hudson L (1985) Administration of adenosine-ribosyl transferase antagonist allows in vivo control of anti-dinitrophenyl response. Int Arch Allergy Appl Immunol 77:358-363.
3. Chiarugi A (2002) Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br J Pharmacol 137:761-770.
4. Chiarugi A and Moskowitz MA (2003) Poly(ADP-ribose) polymerase-1 activity promotes NF-κB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 85:306-317.
5. Cross AH, Manning PT, Keeling RM, Schmidt RE, and Misko TP (1998) Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 88:45-56.
6. De Vries HE, Kuiper J, De Boer AG, Van Berkel TJC, and Breimer DD (1997) The blood-brain barrier in neuroinflammatory disease. Pharmacol Rev 49:143-155.
7. Dobbie MS, Hurst RD, Klein NJ, and Surtees RA (1999) Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-alpha in an in vitro model of the blood-brain barrier. Brain Res 830:330-336.
8. Endres M, Scott GS, Salzman AL, Kun E, Moskowitz M, and Szabó C (1998) Protective effects of 5-iodo-6-amino-1,2-benzopyrone, an inhibitor of poly(ADP-ribose) synthetase against peroxynitrite-induced glial damage and stroke development. Eur J Pharmacol 351:377-382.
9. Ha HC and Snyder SH (2000) Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol Dis 7:225-239.
10. Hartung HP and Rieckmann P (1997) Pathogenesis of immune-mediated demyelination in the CNS. J Neural Transm Suppl 50:173-181.
11. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, et al. (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite. Implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94:2528-2533.
12. Hooper DC, Kean RB, Scott GS, Spitsin SV, Mikheeva T, Morimoto K, Bette M, Röhrenbeck AM, Dietzschold B, and Weihe E (2001) The CNS inflammatory response to neurotropic virus infection is peroxynitrite-dependent. J Immunol 167:3470-3477.
13. Hooper DC, Morimoto K, Bette M, Weihe M, Koprowski H, and Dietzschold B (1998a) Collaboration of antibody and inflammation in the clearance of rabies virus from the CNS. J Virol 72:3711-3719.
14. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, and Spitsin SV (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes and tissue damage in a mouse model of multiple sclerosis. FASEB J 14:691-698.
15. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, and Koprowski H (1998b) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95:675-680.
16. Kean RB, Spitsin SV, Mikhaeva T, Scott GS, and Hooper DC (2000) The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the CNS in experimental allergic encephalomyelitis through maintenance of blood-CNS barrier integrity. J Immunol 165:6511-6518.
17. King SL, McNerney R, Whitley GS, and Johnstone AP (1989) Differential role for ADP-ribosylation in gene expression during the activation of T lymphocytes by various stimuli. Immunology 67:258-262.
18. Koedel U, Winkler F, Angele B, Fontana A, and Pfister H-W (2002) Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase. J Cereb Blood Flow Metab 22:39-49.
19. Kraus WL and Lis JT (2003) PARP goes transcription. Cell 113:677-683.
20. LaPlaca MC, Zhang J, Raghupathi R, Li J-H, Smith F, Bareyre FM, Snyder SH, Graham DI, and McIntosh TK (2001) Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats. J Neurotrauma 18:369-376.
21. Love S, Barber R, and Wilcock GK (1999) Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 122:247-253.
22. Mabley JG, Jagtap P, Perretti M, Getting SJ, Salzman AL, Virag L, Szabó E, Soriano FG, Liaudet L, Abdelkarim GE, et al. (2001) Anti-inflammatory effects of a novel, potent inhibitor of poly(ADP-ribose) polymerase. Inflamm Res 50:561-569.
23. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Gaustella DB, Dawson VL, and Dawson TM (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced Parkinsonism. Proc Natl Acad Sci USA 96: 5774-5779.
24. McNerney R, Tavasolli M, Shall S, Brazinski A, and Johnstone A (1989) Changes in mRNA levels of poly(ADP-ribose) polymerase during activation of human lymphocytes. Biochem Biophys Acta 1009:185-187.
25. Scott GS, Hake P, Kean RB, Virág L, Szabó C, and Hooper DC (2001a) Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J Neuroimmunol 117:78-86.
26. Scott GS, Hake P, Salzman AL, and Szabó C (1998) Inhibition of poly(ADP-ribose) synthetase prevents the neurological development of experimental allergic encephalomyelitis. FASEB J 12:A753.
27. Scott GS, Kean RB, Southan GJ, Szabó C, and Hooper DC (2001b) Effect of mercaptoethylguanidine scavengers of peroxynitrite on the development of experimental allergic encephalomyelitis in PLSJL mice. Neurosci Lett 311:125-128.
28. Scott GS, Virág L, Szabó C, and Hooper DC (2003) Peroxynitrite-induced oligodendrocyte toxicity is not dependent on poly(ADP-ribose) polymerase activation. Glia 41:105-116.
29. Sharp C, Warren A, Oshima T, Williams L, Li JH, and Alexander JS (2001) Poly ADP-ribose-polymerase inhibitors prevent the upregulation of ICAM-1 and E-selectin in response to Th1 cytokine stimulation. Inflammation 25:157-163.
30. Skaper SD (2003) Poly(ADP-ribose) polymerase-1 in acute neuronal death and inflammation. A strategy for neuroprotection. Ann NYAcad Sci 993:217-228.
31. Soriano FG, Virág L, Jagtap P, Szabó E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KGK, Salzman AL, et al. (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108-113.
32. Szabó C (2002a) Cell Death: the Role of PARP. CRC Press LLC, Boca Raton, Florida.
33. Szabó C (2002b) Role of poly(ADP-ribose) synthetase in inflammation. Eur J Pharmacol 350:1-19.
34. Szabo C (2003) Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 140-141:105-112.
35. Szabó C, Virág L, Cuzzocrea S, Scott GS, Hake P, O'Connor M, Zingarelli B, Salzman AL, and Kun E (1998) Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthetase. Proc Natl Acad Sci USA 95:3867-3872.
36. Touil T, Deloire-Grassin MSA, Vital C, Petry KG, and Brochet B (2001) In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12:3637-3644.
37. Van der Veen RC, Hinton DR, Incardonna F, and Hofman FM (1997) Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol 77:1-7.
38. Virág L and Szabó C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375-429.
39. Weltin D, Picard K, Aupeix K, Varin M, Oth D, Marchal J, Dufour P, and Bichoff P (1995) Immunosuppressive activities of 6(5H)-phenanthridinone, a new poly(ADP-ribose) polymerase inhibitor. Int J Immunopharmacol 17:265-271.
40. Zingarelli B, Salzman AL, and Szabó C (1998) Genetic disruption of poly(ADP-Ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 83:85-94.